Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

Researchers at University of California San Diego School of Medicine have developed a new, easy-to-use blood test score that ...

A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it ...

The Alzheimer’s ‘clock’ could make it easier to treat the disease early, before memory problems appear. A simple blood test might one day serve as a molecular ‘clock’ that predicts not only whether ...

Scientists discovered that certain blood proteins linked to brain injury and inflammation strongly correlate with early signs of memory and cognitive decline, especially in Hispanic and Latino adults.

A cohort study of 5607 patients with chronic kidney disease reveals that having more advanced disease, particularly higher proteinuria levels, is linked to an increased risk for cognitive impairment.

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

These changes can reduce blood flow to the brain and affect how brain cells communicate. CKD is also closely linked to high ...

Objective Cardiovascular diseases (CVD) remain the leading cause of mortality globally, necessitating early risk ...